Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

GRECO-2: A Randomized, Phase 2b Study of GC4711 in Combination With Stereotactic Body Radiation Therapy (SBRT) in the Treatment of Unresectable or Borderline Resectable Nonmetastatic Pancreatic Cancer

NCT04698915 is registered in ClinicalTrials.gov with Galera Therapeutics, Inc. as lead sponsor.

NCT NCT04698915
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04698915 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
GRECO-2: A Randomized, Phase 2b Study of GC4711 in Combination With Stereotactic Body Radiation Therapy (SBRT) in the Treatment of Unresectable or Borderline Resectable Nonmetastatic Pancreatic Cancer
Lead sponsor
Galera Therapeutics, Inc.
Phase
Phase 2
Overall status
Terminated
Start date
May 7, 2021
Completion date
November 30, 2023
Enrollment
177 (actual)
Sites
35

Conditions

As the registry lists them; a condition with its own page is linked.

borderline resectable pancreatic cancer, sbrt, unresectable pancreatic cancer